The medical device company’s new strategy focuses on acquiring and partnering with sleep specialty medical providers, driving revenue growth and a path toward positive cash flow.
Pediatric OSA diagnosis and therapy tools have advanced. Even toddlers have more options.
The company’s CARE oral devices for sleep apnea are now eligible for Medicare reimbursement, broadening accessible treatment alternatives for beneficiaries.
In its fourth-quarter and full-year 2023 highlights, Vivos Therapeutics reported positive business momentum following receiving US Food and Drug Administration clearance for its oral appliances to treat severe obstructive sleep apnea last November.
Read More
Tremblors from the Philips CPAP recall continue to shift the therapy landscape in sleep medicine.
Read More
Vivos highlighted certain market developments that it says are creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies.
Read More
Vivos announced it is seeing positive preliminary metrics after receiving FDA clearance for its CARE oral appliances to treat severe OSA.
Read More
Vivos Therapeutics reported a decrease in revenue for the third quarter, juxtaposed against its efforts to expand internationally and form strategic partnerships in the sleep treatment market.
Read More
Vivos Therapeutics signed a US nationwide agreement with Lincare, a supplier of in-home respiratory therapy products and services, for the distribution of Vivos’ oral appliances.
Read More
Vivos Therapeutics’ flagship daytime-nighttime appliance (DNA) will be tested against CPAP in a clinical trial at Stanford Medicine.
Read More
Vivos Therapeutics Inc signed an exclusive distribution agreement to bolster its international expansion across the Middle East-North Africa region.
Read More
Vivos Therapeutics reported a decline in product revenue and enrollments in the second quarter, a dip it attributed to governmental investigations into third parties offering non-FDA-approved sleep apnea treatments.
Read More
The company has made strides in recovering from COVID-19 setbacks and is now on track to achieve positive cash flow by mid-2024, a quarter ahead of schedule, according to the company’s CEO.
Read More
With AirwayRx, clinicians can deliver aesthetic finishes to their obstructive sleep apnea patients without having to work against the treatment philosophy of their clear aligner company, according to Candid.
Read More
This development immediately makes benefits of the mmRNA device available to millions of Medicare beneficiaries who seek effective treatment for mild to moderate OSA.
Read More
On MyoCorrect, therapists will provide Vivos-trained providers access to orofacial myofunctional therapy as a component to OSA treatment.
Read MoreBy unifying efforts of medical doctors and dentists, Vivos expects to see more patients being screened, diagnosed, and treated with the Vivos System.
Read MoreDeveloped in collaboration with Lyon Dental, AireO2 contains features for billing services, practice management systems, and more.
Read More